Jose-Ignacio Rodriguez-Barbosa
Overview
Explore the profile of Jose-Ignacio Rodriguez-Barbosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Rio M, de Juan C, Roncador G, Caleiras E, Alvarez-Esteban R, Perez-Simon J, et al.
Front Immunol
. 2023 Apr;
14:1113858.
PMID: 37033927
Introduction: A high frequency of mutations affecting the gene encoding Herpes Virus Entry Mediator (HVEM, TNFRSF14) is a common clinical finding in a wide variety of human tumors, including those...
2.
Del Rio M, Perez-Simon J, Rodriguez-Barbosa J
Front Immunol
. 2022 Jul;
13:887348.
PMID: 35795681
The contribution of natural killer (NK) cells to tumor rejection in the context of programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) blockade is a matter of intense debate. To elucidate the...
3.
von Knethen A, Rodriguez-Barbosa J
Front Immunol
. 2021 Nov;
12:795495.
PMID: 34777402
No abstract available.
4.
Del Rio M, Nguyen T, Tesson L, Heslan J, Gutierrez-Adan A, Fernandez-Gonzalez R, et al.
Transl Res
. 2021 Aug;
239:103-123.
PMID: 34461306
CD160 is a member of the immunoglobulin superfamily with a pattern of expression mainly restricted to cytotoxic cells. To assess the functional relevance of the HVEM/CD160 signaling pathway in allogeneic...
5.
Rodriguez-Barbosa J, Schneider P, Graca L, Buhler L, Perez-Simon J, Del Rio M
Int J Mol Sci
. 2020 May;
21(9).
PMID: 32397343
Regulatory T cells (Tregs) are essential for the maintenance of tolerance to self and non-self through cell-intrinsic and cell-extrinsic mechanisms. Peripheral Tregs survival and clonal expansion largely depend on IL-2...
6.
Rodriguez-Barbosa J, Azuma M, Zelinskyy G, Perez-Simon J, Del Rio M
Cancer Immunol Immunother
. 2020 Feb;
69(6):1001-1014.
PMID: 32088772
The expression of PD-L1 on tumor cells or within the tumor microenvironment has been associated with good prognosis and sustained clinical responses in immunotherapeutic regimens based on PD-L1/PD-1/CD80 immune checkpoint...
7.
Kim T, Park G, Kim J, Lim S, Kim J, Im K, et al.
Nat Commun
. 2019 Jul;
10(1):3258.
PMID: 31332204
CD160 and BTLA both bind to herpes virus entry mediator. Although a negative regulatory function of BTLA in natural killer T (NKT) cell activation has been reported, whether CD160 is...
8.
Rodriguez-Barbosa J, Fernandez-Renedo C, Moral A, Buhler L, Del Rio M
Cell Mol Immunol
. 2019 Jan;
16(3):314.
PMID: 30635646
In this article, one of the grating agencies requested us to incorporate the information, Spanish Government and co-funded by European Union ERDF/ESF, "Investing in your future", in the acknowledgments section....
9.
Del Rio M, Moral A, Fernandez-Renedo C, Buhler L, Perez-Simon J, Chaloin O, et al.
Transl Res
. 2016 Oct;
181:83-95.e3.
PMID: 27702550
CD160 is a glycosylphosphatidylinositol-anchored protein of the immunoglobulin superfamily. It exhibits a pattern of expression coincident in humans and mice that is mainly restricted to cytotoxic cells and to all...
10.
Rodriguez-Barbosa J, Fernandez-Renedo C, Moral A, Buhler L, Del Rio M
Cell Mol Immunol
. 2016 Mar;
14(6):497-510.
PMID: 26924526
The molecular pathways contributing to humoral-mediated allograft rejection are poorly defined. In this study, we assessed the role of the herpesvirus entry mediator/B- and T-lymphocyte attenuator (HVEM/BTLA) signalling pathway in...